A 2025 wave of state 'trigger bills' would automatically legalize or regulate psychedelic therapy the moment federal law changes — and the strategy is gaining traction across party lines.
A trigger bill is a state law that sits dormant until Washington does something first. The bill passes a state legislature and gets signed by a governor, but it does not change what is legal in that state — not yet. It only changes the law if and when a named federal event occurs.
For psychedelic trigger bills, the named event is usually the FDA approving a specific psilocybin drug product. Once the FDA acts, the state's existing Schedule I classification automatically drops for that approved drug, and doctors can prescribe it without waiting for another state vote.
The result is a two-key system: the state legislature turns one key in advance, and the federal government holds the other. Both keys must turn before the door opens.
State legislators, especially Republicans, face pressure from two directions at once. Veterans and mental health advocates want faster access to promising therapies. Colleagues and constituents want assurance that the state is not legalizing a controlled substance ahead of federal science.
A trigger bill lets a legislator vote yes on veterans' mental health without voting to override federal drug law. The bill says: we are ready to move the moment Washington clears the way. That framing was powerful enough in Iowa to win a 92–0 House vote and a 47–0 Senate vote — in a Republican supermajority legislature.
Most 2025 trigger bills require FDA approval of a psilocybin drug product before the state law activates. Several bills also require DEA rescheduling — the agency must move psilocybin out of Schedule I before the state exemption applies.
The most common target is a drug called COMP360, made by the British biotech company Compass Pathways. COMP360 uses a specific chemical form of psilocybin called crystalline polymorph psilocybin. Most 2025 trigger bills use this exact phrase in their text, which limits the exemption to COMP360 or any drug using the same patented crystal structure — not to natural psilocybin mushrooms or other formulations.
FDA approval alone does not move a drug out of Schedule I. The DEA must also act — either on its own or in response to an FDA recommendation — to reschedule the drug federally. Some trigger bills require both steps; others activate on FDA approval alone and assume DEA rescheduling will follow. Virginia's 2026-enacted bills direct the Board of Pharmacy to act within one quarter of the FDA publication date, and allow rescheduling consistent with whatever schedule the federal government assigns.
Some trigger-bill language is broader than "DEA rescheduling or FDA approval." Certain bills specify the trigger fires upon any federal action that removes Schedule I status for the substance — and that language is wide enough to include a federal court ruling. A federal district court ruling that invalidates a Schedule I classification, or limits DEA enforcement authority in a therapeutic context, could technically qualify as a trigger under some bill drafts.
This is a point most coverage of trigger bills overlooks entirely. The difference between "DEA rescheduling" and "any federal action removing Schedule I status" is consequential. The latter opens a judicial trigger path that no one is specifically planning for — but that advocates and drafters should know exists. Legislators writing trigger bills should read the trigger clause precisely before finalizing bill text.
At least nine states introduced trigger-style legislation in 2025 and early 2026. Outcomes split across three categories: enacted, vetoed, and still pending.
Virginia had the clearest success. Governor Abigail Spanberger signed HB 1347 and SB 379 into law. Both bills direct the Virginia Board of Pharmacy to reschedule any FDA-approved psilocybin formulation for administration in a health care setting at the Board's next quarterly meeting following 30 days from publication in the Federal Register. Senator Jennifer Boysko introduced SB 379 citing high veteran suicide rates and promising PTSD trial results. Virginia SB 1135 from the 2025 session was an earlier version that Governor Youngkin vetoed, but the 2026 versions under Spanberger succeeded.
Iowa's story is a cautionary one. HF 14 was refiled as HF 383 and passed the House 92–0 and the Senate 47–0. Governor Kim Reynolds vetoed it on June 11, 2025, saying the bill surrendered too much regulatory authority to federal officials and could create legal uncertainty. The veto surprised even the bill's Republican floor manager, who called it unexpected. Iowa remains a Schedule I state for psilocybin.
Colorado HB 25-1063 passed committee 12–1 in January 2025. Sponsored by Representatives Anthony Hartsook and Kyle Brown with bipartisan co-sponsors, it amends Colorado's Uniform Controlled Substances Act to exempt prescription drugs containing crystalline polymorph psilocybin once the FDA approves them. Compass Pathways supported the bill and sent staff to testify. It was signed into law in June 2025. Colorado already has a broader psilocybin program under Proposition 122; HB 25-1063 adds a separate pharmaceutical lane.
West Virginia HB 3343 passed the House. It adds crystalline polymorph psilocybin to the list of permitted substances if the FDA approves and the DEA schedules or deschedules it. Compass Pathways backed this bill as well. The measure stalled in the Senate before the session ended.
Rhode Island HB 5186 takes a different approach. It creates a personal possession and cultivation allowance for up to one ounce of psilocybin for adults, with a broader trigger: if the FDA reschedules psilocybin through an access program, the Department of Health must establish rules for cultivation, distribution, and medical prescription. The committee recommended it be held for further study in February 2025. The bill has a sunset date of July 1, 2027 if enacted.
Iowa SSB 1177 was the Senate companion to HF 14. Minnesota introduced HF 2699 covering decriminalization. Several states used broader trigger language tied to any DEA rescheduling, not just the crystalline polymorph. Psychedelic Alpha counted at least nine Compass-backed rescheduling trigger bills across US states in 2025.
Compass Pathways, the British company developing COMP360 for treatment-resistant depression, actively lobbied for narrow trigger bills in multiple states in 2025. The company's Senior Manager of Advocacy and State Government Policy testified in support of Colorado HB 25-1063 at its first committee hearing.
The strategy is commercially specific. By writing bills around crystalline polymorph psilocybin — the patented form Compass uses — and not around psilocybin broadly, the bills pre-approve only COMP360 or drugs using the same structure. A competitor with a different psilocybin formulation would not automatically benefit.
Critics including advocates who backed Oregon's Measure 109 and Colorado's Proposition 122 argue that these bills serve pharmaceutical interests more than patients. A trigger bill tied to pharmaceutical psilocybin would not expand access to the plant-based psilocybin therapy models already operating in Colorado and Oregon. It would create a separate, prescription-only lane.
Oregon and Colorado passed direct legalization — their laws created access programs immediately, without waiting for Washington. Trigger bills take the opposite approach, deferring entirely to federal action. The table compares the two models.
| Feature | Trigger bill model | Direct legalization model | Working-group / study approach |
|---|---|---|---|
| What it does immediately | Writes therapy program into statute; dormant until trigger fires | Creates an active program with a defined launch date | Creates a commission or agency study; no program authorized |
| When access opens | Only after FDA approval or DEA rescheduling | On the law's effective date (typically 1–3 years after passage) | Very long — commission → second bill → rulemaking → launch |
| Second bill required? | No — program launches automatically on trigger | No — program authorized directly | Yes — commission findings require a second legislative session |
| Substances covered | Usually only the FDA-approved pharmaceutical form | Natural and/or synthetic, depending on the law | None — study generates recommendations, not access |
| Federal conflict risk | Low — activates only when federal law already changed | High — operates under federal Schedule I prohibition | None — a study creates no authorization |
| Political difficulty | Lower — bipartisan, defers to federal authority | Higher — requires legislators to vote against federal law | Lowest — supporting research is easy to defend |
| Examples | CO HB 25-1063, VA HB 1347/SB 379, WV HB 3343 | Colorado Prop 122, Oregon Measure 109 | Multiple state "task force" bills introduced 2021–2023 |
| Best for | States that want reform but need federal cover | States with voter or legislative supermajority support | States still building political consensus |
The trigger bill sits between the other two on almost every axis. It is more committed than a working group and less exposed than direct legalization. That middle position is why it gained traction across states that would not have passed direct legalization in 2025.
When a trigger bill is a win: in conservative states, it positions the state to move fast once Washington acts. When it falls short: for patients who need access now, a trigger bill offers nothing — the federal trigger may never arrive, or may take years.
MDMA is less common in trigger bills than psilocybin, and the reason is the FDA's August 2024 decision. The FDA rejected Lykos Therapeutics' new drug application for MDMA-assisted therapy for PTSD and required an additional Phase 3 trial before reconsidering. That decision reset the timeline for any MDMA federal trigger by several years.
Rhode Island HB 5186 uses broader language that could cover MDMA if the FDA ever reschedules it through a general access program. Most other 2025 trigger bills are silent on MDMA or explicitly limited to psilocybin. Advocates tracking MDMA legislation should watch the legalization tracker for updates as Lykos prepares for additional trials.
See our full MDMA guide and where MDMA is legal worldwide for the current access landscape.
The fate of every pending trigger bill depends on one thing: whether the FDA approves a psilocybin drug product. As of mid-2026, Compass Pathways' COMP360 is in Phase 3 trials. If those trials succeed and the FDA approves the drug, every enacted trigger bill in states like Virginia and Colorado would activate within weeks.
Iowa and West Virginia remain positioned to re-file. The unanimous votes in Iowa show that legislative will exists — the veto was an executive, not a legislative, obstacle. A different governor, or a legislature that waits for more clinical data, could change the outcome in a future session.
The April 2026 executive order on psychedelics directed the FDA and DEA to accelerate their review processes for psychedelic therapies, which could compress the remaining timeline. Use the psychedelic legalization tracker to follow FDA milestones and new state filings as they happen.
A psychedelic trigger bill is a state law that pre-authorizes psilocybin or MDMA therapy but does not activate until a specific federal event occurs — usually FDA approval of the drug or DEA rescheduling out of Schedule I. Once the federal trigger is hit, the state change happens automatically without requiring another vote.
As of mid-2026, Virginia is the clearest success story: Governor Abigail Spanberger signed HB 1347 and SB 379, which direct the Board of Pharmacy to reschedule psilocybin at its next quarterly meeting after FDA approval. West Virginia's HB 3343 also passed the House. Iowa's HF 383 passed both chambers 92–0 and 47–0 but was vetoed by Governor Kim Reynolds in June 2025.
Most trigger bills use FDA approval of a psilocybin drug product as the key event. Some also require DEA rescheduling. The most common target is FDA approval of COMP360, Compass Pathways' synthetic crystalline psilocybin formulation, which is in Phase 3 trials. MDMA trigger bills would need a new FDA NDA after the August 2024 rejection.
Trigger bills let Republican legislators support medical access for veterans suffering from PTSD without contradicting federal law or appearing to legalize a Schedule I drug. The bills only act if Washington acts first, which appeals to lawmakers who prefer to defer to federal authority. Iowa's HF 383 passed 92–0 in the House and 47–0 in the Senate — an almost purely Republican legislature.
Most 2025 trigger bills target psilocybin, not MDMA. MDMA's path was set back when the FDA rejected Lykos Therapeutics' new drug application in August 2024 and required an additional Phase 3 trial. A few bills cover MDMA in broader language, but no state has enacted an MDMA-specific trigger law.
A failed or vetoed trigger bill leaves the state's existing Schedule I classification in place. Psilocybin and MDMA remain illegal under state law until a future legislature acts. Iowa, for example, remains a Schedule I state after the June 2025 veto, and advocates are expected to re-file in the next session.
State trigger bills move quickly once FDA decisions land. The legalization tracker follows every active state bill and federal milestone so you see changes the day they happen.
Get Psychedelic Trigger Bills 2025: State Laws That Wait for Washington updates
New votes, rules, court rulings, and access changes for Psychedelic Trigger Bills 2025: State Laws That Wait for Washington — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.